Waters Corporation Stock Receives Strong Analyst Ratings Amid Solid Earnings Performance
Waters Corporation (WAT) has outperformed both the S&P 500 Index ($SPX) and the State Street Health Care Select Sector SPDR ETF (XLV) over the past year, with its stock rising nearly 43% compared to gains of 19.3% and 25.3%, respectively. The company reported better-than-expected Q2 earnings in August 2026, driven by strong demand for lab equipment and testing supplies. Analysts have responded positively, with a consensus rating of 'Moderate Buy' based on 14 'Strong Buy' ratings, one 'Moderate Buy,' and eight 'Holds.' Barclays analyst Luke Sergott raised the price target to $460 while maintaining an 'Overweight' rating. The mean price target is at $438.43, indicating a potential upside of around 4.1% from current levels. Waters Corporation has consistently exceeded earnings expectations in recent quarters and revised its fiscal year guidance upward for adjusted EPS to between $14.45 - $14.65.
Topics: financial results stock performance Waters Corporation